Chantix in JAMA
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's prescription therapy Chantix (varenicline) was "significantly more efficacious" for smoking cessation after 12- and 24-week periods than GlaxoSmithKline's Zyban (bupropion SR), according to a study published in the July 5 issue of the Journal of the American Medical Association. David Gonzales, PhD, Oregon Health & Science University, et al., randomized 1,025 healthy smokers 18 to 75 years old, with fewer than three months smoking abstinence. The groups were treated with one of the two drugs or placebo and took exhaled carbon monoxide tests to confirm abstinence. For weeks 9-12, 44% of the Chantix group stayed abstinent compared to 17.7% for the placebo group and 29.5% for the Zyban group. Chantix received approval in May (1"The Tan Sheet" May 15, 2005, In Brief)...
You may also be interested in...
Rx smoking cessation pill
FDA has approved Pfizer's smoking cessation drug Chantix (varenicline) for prescription use, the agency announces May 11. The drug, which Pfizer originally had intended to market as Champix, is the first nicotine agonist approved by FDA, and the first new Rx medication approved for smoking cessation in more than a decade, according to the firm. Varenicline works by binding to nicotine receptors in the brain, thereby "providing some nicotine effects to ease withdrawal symptoms and...blocking the effects of nicotine from cigarettes if [people] resume smoking," FDA states. Pfizer expects Chantix to launch in the second half of 2006. The firm has stated in the past that it will draw from its Nicorette experience when developing DTC ads for Chantix (1"The Tan Sheet" Feb. 9, 2004, p. 5)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.